EGFR, HER2 & Receptor Tyrosine Kinases

Cat. No.

AT0334

CAS No.

1832713-21-9

KHK-2866

KHK-2866 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target human heparin-binding EGF-like growth factor (HBEGF). This antibody has a predicted molecular weight of 145 kDa. KHK-2866 is utilized in research applications to study the role of HBEGF in various biological processes and disease states, including cancer and cardiovascular diseases.

Cat. No.

AT0336

CAS No.

2765077-69-6

Dalmitamig

Synonyms: bsAb7075; REGN-7075

Dalmitamig is a human monoclonal antibody of the IgG4κ subtype that targets both EGFR and CD28. For experiments requiring precise isotype controls, the recommended control is Human IgG4 (S228P) kappa Isotype Control, ensuring accurate assessment of antibody specificity and function.

Cat. No.

AT0338

CAS No.

905703-97-1

Ganitumab

Synonyms: AMG 479; Human Anti-IGF1R Recombinant Antibody

Ganitumab (AMG 479) is a recombinant human monoclonal antibody specifically targeting the human type 1 insulin-like growth factor receptor (IGF1R). This antibody exhibits high specificity and affinity for murine IGF1R, with a dissociation constant (K_D) of 0.22 nM, effectively inhibiting the interaction between murine IGF1R and its ligands, IGF1 and IGF2. Ganitumab is primarily utilized in oncological research to study the role of the IGF1R pathway in cancer progression and potential therapeutic interventions.

Cat. No.

AT0422

CAS No.

2460399-44-2

Ozuriftamab

Synonyms: BA302

Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC.

Cat. No.

AT0439

Anti-EphA2 Antibody (1C1)

Synonyms: MEDI-547 antibody

The Anti-EphA2 Antibody (1C1), also known as MEDI-547, is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the EphA2 receptor, a critical component involved in various cellular processes including angiogenesis, neurogenesis, and cancer progression. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, and has a predicted molecular weight of 146.68 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT0452

CAS No.

2361055-48-1

Mipasetamab

Mipasetamab is an IgG1κ monoclonal antibody specifically designed to target AXL, a member of the TAM family of receptor tyrosine kinases. This antibody plays a crucial role in the synthesis of ADCT-601 (Mipasetamab uzoptirine), an antibody-drug conjugate (ADC) that selectively binds to the AXL receptor. ADCT-601 demonstrates significant antitumor activity, leveraging the specificity of Mipasetamab to deliver cytotoxic agents directly to AXL-expressing tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is pivotal for research focused on the development of targeted cancer therapies, particularly in studies investigating the role of AXL in cancer progression and resistance mechanisms.

Cat. No.

AT0482

Anti-EphB2 Antibody

The Anti-EphB2 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the EphB2 receptor, a member of the Eph family of receptor tyrosine kinases involved in developmental processes and disease states such as cancer. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is suitable for use in various immunological assays to study EphB2 function and expression.

Cat. No.

AT0489

Anti-MSPR/RON/CD136 Antibody (H5B14)

Synonyms: H5B14

The Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the MSPR/RON/CD136 antigen. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 156.7 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control should be utilized as the isotype control for this antibody. This product is essential for researchers focusing on the biological pathways and disease associations involving the MSPR/RON/CD136 protein.

Cat. No.

AT0516

CAS No.

1133766-06-9

Onartuzumab

Synonyms: MetMAb

Onartuzumab (MetMAb) is a humanized, affinity-matured monovalent monoclonal antibody specifically targeting the MET receptor. This antibody effectively inhibits hepatocyte growth factor (HGF) binding, thereby preventing receptor phosphorylation and downstream signaling. Characterized by pharmacokinetics akin to those of typical antibodies, Onartuzumab demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic development.

Cat. No.

AT0537

CAS No.

1471999-69-5

Depatuxizumab

Synonyms: ABT-806

Depatuxizumab is a brain-penetrant, humanized monoclonal antibody specifically targeting the epidermal growth factor receptor (EGFR). This antibody demonstrates selective inhibition of both mutant EGFRvIII and wild-type EGFR, effectively impeding the growth of xenograft models that express these receptors. Depatuxizumab is primarily utilized in cancer research, offering significant utility in the study of tumor biology and therapeutic antibody development.

Cat. No.

AT0583

CAS No.

1969309-56-5

Zenocutuzumab

Synonyms: MCLA-128; PB4188; R040517

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody engineered to target the extracellular domains of HER2 and HER3 with its two distinct Fab arms. This dual specificity facilitates the inhibition of downstream signaling pathways that are critical for tumor growth and survival, making it a valuable tool for research in cancer biology, particularly in studies focused on breast and gastric cancers.

Cat. No.

AT0599

CAS No.

180288-69-1

Trastuzumab

Synonyms: Anti-Human HER2; Humanized Antibody

Trastuzumab is a humanized IgG1 monoclonal antibody specifically designed for targeting and neutralizing HER2, a protein overexpressed in certain invasive breast cancers. This antibody is crucial for research focused on HER2-positive metastatic breast cancer and HER2-positive gastric cancer, providing a valuable tool for understanding disease mechanisms and developing therapeutic strategies.

Cat. No.

AT0608

CAS No.

339186-68-4

Matuzumab

Synonyms: EMD 72000

Matuzumab (EMD 72000) is a humanized monoclonal antibody designed to target and inhibit the epidermal growth factor receptor (EGFR). By binding to EGFR, Matuzumab prevents its activation and the subsequent downstream signaling pathways, effectively inhibiting tumor growth. This antibody is utilized primarily in research focused on cancer biology, particularly in studies investigating the mechanisms of tumor progression and therapeutic intervention.

Cat. No.

AT0613

CAS No.

1509928-04-4

Istiratumab

Synonyms: MM 141; MM-005

Istiratumab (M-6495) is a bispecific monoclonal antibody designed to target both the Insulin-like Growth Factor 1 Receptor (IGF-1R) and the ErbB3 receptor. This antibody facilitates the degradation of these receptors via the proteasome pathway, a mechanism that may be critical in modulating cellular growth and survival pathways. Istiratumab is primarily used in cancer research, where it serves as a tool to investigate the role of IGF-1R and ErbB3 in tumor biology and therapeutic response.

Cat. No.

AT0614

CAS No.

2636710-06-8

Anvatabart

Synonyms: ARX-788

Anvatabart is a human IgG1 κ monoclonal antibody targeting ERBB2. For accurate control experiments, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0639

CAS No.

205923-56-4

Cetuximab

Synonyms: C225

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Cat. No.

AT0640

RGX-019

RGX-019 is a humanized monoclonal antibody currently under investigation as a drug candidate. It specifically targets the MER proto-oncogene tyrosine kinase (MERTK), a receptor tyrosine kinase implicated in the regulation of various cellular processes including survival, migration, and differentiation. This targeted approach holds potential for therapeutic applications in oncology and diseases characterized by abnormal cell proliferation and survival.

Cat. No.

AT0641

Hersintuzumab

Hersintuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting ERBB2/HER2/CD340. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. Hersintuzumab is applicable in research focused on cancer biology, particularly in studies investigating the role of the ERBB2/HER2/CD340 in tumor growth and progression.

Cat. No.

AT0648

CAS No.

1312305-12-6

Vofatamab

Synonyms: B-701; MFGR-1877S; RG-7444

Vofatamab (B-701) is a monoclonal antibody that selectively targets the fibroblast growth factor receptor 3 (FGFR3). It effectively inhibits the activation of both the wild-type and mutant forms of this receptor. This antibody is particularly useful in research focused on metastatic urothelial carcinoma (mUC), providing a critical tool for investigating the role of FGFR3 in cancer progression and potential therapeutic interventions.

Cat. No.

AT0674

HuGAL-F2

HuGAL-F2 is a monoclonal antibody derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting Fibroblast Growth Factor 2 (FGF2). This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control experiments, Human IgG2 kappa, Isotype Control is recommended. HuGAL-F2 is suitable for use in a variety of biochemical and cellular research applications to study the role and function of FGF2 in biological processes.

Cat. No.

AT0675

CAS No.

1781223-80-0

Telisotuzumab

Synonyms: ABT-700

Telisotuzumab (ABT-700) is a human recombinant bivalent antibody designed to target the hepatocyte growth factor receptor (MET). It binds to c-Met with high affinity, effectively inhibiting c-Met signaling. This antibody demonstrates significant antitumor activity, making it a valuable tool for research in cancer therapy, particularly in studies focusing on the role of c-Met in tumor growth and metastasis.

Cat. No.

AT0677

CAS No.

667901-13-5

Zalutumumab

Zalutumumab is a fully human IgG1 monoclonal antibody exhibiting high affinity for the epidermal growth factor receptor (EGFR). It specifically binds to domain III of EGFR, effectively blocking the receptor's interaction with its natural ligand, EGF. This interaction inhibits the receptor's activation by steric hindrance, preventing its transition to an active conformation. Zalutumumab demonstrates binding affinities with half-maximal effective concentrations (EC50) of 7 nM for the whole IgG and 19 nM for its Fab fragment. This antibody is primarily utilized in cancer research, providing a valuable tool for investigating EGFR's role in oncogenic processes and therapeutic interventions.

Cat. No.

AT0680

CAS No.

2728655-31-8

Veligrotug

Veligrotug is a chimeric monoclonal antibody of the IgG1-kappa isotype, specifically targeting the insulin-like growth factor 1 receptor (IGF1R, CD221). This antibody is designed for the precise detection and inhibition of IGF1R, a receptor tyrosine kinase implicated in numerous cellular processes including cell growth, differentiation, and survival. Veligrotug is utilized in research focused on cancer biology, metabolic disorders, and developmental biology, providing valuable insights into IGF1R's role in disease pathogenesis and therapeutic interventions.

Cat. No.

AT0685

CAS No.

2213450-26-9

Petosemtamab

Synonyms: MCLA 158

Petosemtamab (MCLA 158) is a bifunctional monoclonal antibody targeting both EGFR and LGR5 with dissociation constants (Kd) of 0.22 nM and 0.86 nM, respectively. This antibody effectively blocks EGFR signaling and induces receptor degradation specifically in LGR5-positive cancer cells. Petosemtamab is primarily utilized in research focused on solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for investigating the pathophysiology and potential therapeutic strategies for these malignancies.

Cat. No.

AT0687

CAS No.

2851478-58-3

Umikibart

Umikibart is a humanized IgG4κ monoclonal antibody specifically targeting HGF (hepatocyte growth factor). For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and configuration make Umikibart suitable for detailed studies in HGF-related pathways and potential therapeutic applications.